NELSEN ROBERT — SEC insider filings
SEC reporting owner CIK 1219042. 91 insider filings on record with FilingPulse; latest filed 2026-11-05.
Transaction summary — filings shown
Covers the 50 most recent of 91 filings on record, filed 2022-08-26 to 2026-11-05. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 40 legs across 21 filings — 26,856,152 shares, $241,089,954 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 16,000 shares, $39,840 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 125.
- Largest priced transaction: purchase of 1,432,224 shares @ $18.00 ($25,780,032) in Metsera, Inc., filed 2025-02-03.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Prime Medicine, Inc. (PRME) | Director, 10% owner | 8 | 4 legs · 7,030,300 sh · $43,599,990 | — | 16 |
| Metsera, Inc. (MTSR) | Director, 10% owner | 2 | 2 legs · 2,222,222 sh · $39,999,996 | — | 9 |
| Lyell Immunopharma, Inc. (LYEL) | 10% owner | 6 | 2 legs · 2,809,352 sh · $37,499,977 | — | 3 |
| Neumora Therapeutics, Inc. (NMRA) | 10% owner | 9 | 20 legs · 3,922,764 sh · $36,430,001 | — | 12 |
| Kardigan, Inc. (KARD) | Director, 10% owner | 2 | 1 leg · 1,250,000 sh · $20,000,000 | — | 4 |
| Aspen Neuroscience, Inc. (ASPE) | 10% owner | 2 | 3 legs · 1,333,333 sh · $19,999,995 | — | 18 |
| Seaport Therapeutics, Inc. (SPTX) | 10% owner | 1 | 1 leg · 1,100,000 sh · $19,800,000 | — | 4 |
| Sana Biotechnology, Inc. (SANA) | Director, 10% owner | 8 | 3 legs · 1,818,181 sh · $9,999,996 | — | 7 |
| Codiak BioSciences, Inc. (CDAK) | 10% owner | 1 | 1 leg · 5,000,000 sh · $7,500,000 | — | 1 |
| Boundless Bio, Inc. (BOLD) | 10% owner | 2 | 2 legs · 200,000 sh · $3,200,000 | 1 leg · 16,000 sh · $39,840 | 12 |
+4 more issuers among the filings shown — every filing appears in the table below.
Insider filings — NELSEN ROBERT
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-05 | 4 | Lyell Immunopharma, Inc. (LYEL) jointly with ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, GILLIS STEVEN, Burow Kristina, BERNS PAUL L, BYBEE CLINTON | Purchase (P): 2,321,262 @ $10.77 | EDGAR |
| 2026-11-02 | 4 | Aspen Neuroscience, Inc. (ASPE) jointly with ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners X, LLC, CRANDELL KEITH, Burow Kristina, GILLIS STEVEN | Purchase (P): 66,666 @ $15 · Conversion (C): 187,182 · Conversion (C): 298,258 · Conversion (C): 286,304 · Conversion (C): 295,490 · Conversion (C): 259,948 · +15 more | EDGAR |
| 2026-10-29 | 3 | Aspen Neuroscience, Inc. (ASPE) jointly with ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners X, LLC, CRANDELL KEITH, Burow Kristina, GILLIS STEVEN | Holdings only — no transactions reported | EDGAR |
| 2026-10-19 | 4 | CITY THERAPEUTICS, INC. (CTY) | Conversion (C): 3,294,900 · Conversion (C): 5,482,309 · Conversion (C): 2,027,006 · Purchase (P): 170,000 @ $18 · Grant/award (A): 22,649 (derivative) @ $0 · Conversion (C): 3,000,000 (derivative) @ $0 · +2 more | EDGAR |
| 2026-10-15 | 3 | CITY THERAPEUTICS, INC. (CTY) | Holdings only — no transactions reported | EDGAR |
| 2026-07-06 | 4 | Boundless Bio, Inc. (BOLD) jointly with CRANDELL KEITH, BYBEE CLINTON, GILLIS STEVEN, Burow Kristina | Option exercise (M): 16,000 @ $1.03 · Sale (S): 16,000 @ $2.49 · Option exercise (M): 16,000 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Kardigan, Inc. (KARD) jointly with ARCH Venture Partners XIII, LLC, ARCH Venture Partners XIII, L.P., ARCH Venture Fund XIII, L.P., CRANDELL KEITH, Burow Kristina, GILLIS STEVEN | Purchase (P): 1,250,000 @ $16 | EDGAR |
| 2026-06-22 | 4 | Kardigan, Inc. (KARD) jointly with ARCH Venture Partners XIII, LLC, ARCH Venture Partners XIII, L.P., ARCH Venture Fund XIII, L.P., CRANDELL KEITH, Burow Kristina, GILLIS STEVEN | Conversion (C): 13,792,035 · Conversion (C): 5,148,587 (derivative) · Conversion (C): 1,204,000 (derivative) · Conversion (C): 2,306,401 (derivative) | EDGAR |
| 2026-06-08 | 4 | Prime Medicine, Inc. (PRME) | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Sana Biotechnology, Inc. (SANA) | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Seaport Therapeutics, Inc. (SPTX) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, Burow Kristina, GILLIS STEVEN | Conversion (C): 2,513,686 · Conversion (C): 2,681,265 · Purchase (P): 1,100,000 @ $18 · Conversion (C): 2,513,686 (derivative) @ $0 · Conversion (C): 2,681,265 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Lyell Immunopharma, Inc. (LYEL) jointly with ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, Burow Kristina, GILLIS STEVEN, BERNS PAUL L, BYBEE CLINTON | Purchase (P): 488,090 @ $25.61 | EDGAR |
| 2025-11-14 | 4 | Metsera, Inc. (MTSR) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P., ARCH Venture Partners XII, L.P., ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, GILLIS STEVEN | Disposition to issuer (D): 18,503,128 · Disposition to issuer (D): 8,313,680 | EDGAR |
| 2025-10-29 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN, BYBEE CLINTON | Purchase (P): 1,915,700 @ $2.61 | EDGAR |
| 2025-08-05 | 4 | Prime Medicine, Inc. (PRME) | Disposition to issuer (D): 39,062 (derivative) · Grant/award (A): 39,062 (derivative) · Disposition to issuer (D): 45,000 (derivative) · Grant/award (A): 45,000 (derivative) | EDGAR |
| 2025-08-01 | 4 | Prime Medicine, Inc. (PRME) | Purchase (P): 3,030,300 @ $3.30 | EDGAR |
| 2025-07-29 | 4 | Lyell Immunopharma, Inc. (LYEL) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH, BYBEE CLINTON | Holdings only — no transactions reported | EDGAR |
| 2025-06-09 | 4 | Sana Biotechnology, Inc. (SANA) | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Prime Medicine, Inc. (PRME) | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2025-02-03 | 4 | Metsera, Inc. (MTSR) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P., ARCH Venture Partners XII, L.P., ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, GILLIS STEVEN | Conversion (C): 16,006,949 · Conversion (C): 7,523,682 · Purchase (P): 1,432,224 @ $18 · Purchase (P): 789,998 @ $18 · Conversion (C): 19,933,333 (derivative) · Conversion (C): 15,000,000 (derivative) · +3 more | EDGAR |
| 2024-07-15 | 4/A | Sana Biotechnology, Inc. (SANA) | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Lyell Immunopharma, Inc. (LYEL) | Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Prime Medicine, Inc. (PRME) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Rapport Therapeutics, Inc. (RAPP) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, Burow Kristina, GILLIS STEVEN | Conversion (C): 3,728,738 @ $0 · Conversion (C): 20,000,000 (derivative) @ $0 · Conversion (C): 11,924,138 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Sana Biotechnology, Inc. (SANA) | Grant/award (A): 54,278 (derivative) @ $0 | EDGAR |
| 2024-06-03 | 4 | Vir Biotechnology, Inc. (VIR) | Grant/award (A): 8,000 @ $0 · Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2024-04-04 | 4 | Boundless Bio, Inc. (BOLD) jointly with CRANDELL KEITH, BYBEE CLINTON, GILLIS STEVEN | Conversion (C): 589,743 · Conversion (C): 787,545 · Conversion (C): 1,048,433 · Purchase (P): 66,667 @ $16 · Purchase (P): 133,333 @ $16 · Conversion (C): 424,908 (derivative) · +6 more | EDGAR |
| 2024-02-20 | 4 | Prime Medicine, Inc. (PRME) | Purchase (P): 3,200,000 @ $6.25 | EDGAR |
| 2024-02-12 | 4 | Sana Biotechnology, Inc. (SANA) | Purchase (P): 363,637 @ $5.50 · Purchase (P): 727,272 @ $5.50 · Purchase (P): 727,272 @ $5.50 | EDGAR |
| 2023-12-12 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN, BYBEE CLINTON | Other (J): 703,061 · Other (J): 1,176,593 | EDGAR |
| 2023-11-15 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN | Purchase (P): 31,653 @ $11.75 · Purchase (P): 3,357 @ $11.98 | EDGAR |
| 2023-11-13 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN | Purchase (P): 69,127 @ $10.78 · Purchase (P): 23,124 @ $11.79 · Purchase (P): 31,079 @ $10.53 · Purchase (P): 11,844 @ $11.37 · Purchase (P): 5,431 @ $11.75 | EDGAR |
| 2023-11-07 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN | Purchase (P): 22,420 @ $11.38 · Purchase (P): 43,082 @ $11.55 · Purchase (P): 30,192 @ $11.50 | EDGAR |
| 2023-09-29 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN | Purchase (P): 16,841 @ $13.06 · Purchase (P): 25,110 @ $13.69 · Purchase (P): 34,560 @ $13.98 | EDGAR |
| 2023-09-27 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN | Purchase (P): 34,000 @ $11.73 · Purchase (P): 24,504 @ $12.31 | EDGAR |
| 2023-09-25 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN | Purchase (P): 40,000 @ $11.14 · Purchase (P): 30,773 @ $10.80 · Purchase (P): 29,967 @ $11.65 | EDGAR |
| 2023-09-20 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN, BYBEE CLINTON | Conversion (C): 684,167 · Conversion (C): 1,144,973 · Conversion (C): 6,895,021 · Conversion (C): 6,576,400 · Conversion (C): 2,124,143 · Purchase (P): 1,500,000 @ $17 · +5 more | EDGAR |
| 2023-09-08 | 4 | Lyell Immunopharma, Inc. (LYEL) | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2023-08-10 | 4 | DA32 Life Science Tech Acquisition Corp. (DALS) jointly with ARCH Venture Fund XI, L.P., ARCH Venture Partners XI, L.P., ARCH Venture Partners XI, LLC, Burow Kristina, GILLIS STEVEN | Other (J): 1,600,000 | EDGAR |
| 2023-06-20 | 4 | Lyell Immunopharma, Inc. (LYEL) | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | Prime Medicine, Inc. (PRME) | Grant/award (A): 39,062 (derivative) @ $0 | EDGAR |
| 2023-06-12 | 4 | Sana Biotechnology, Inc. (SANA) | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2023-05-24 | 4 | Vir Biotechnology, Inc. (VIR) | Grant/award (A): 6,027 @ $0 · Grant/award (A): 12,054 (derivative) @ $0 | EDGAR |
| 2023-01-06 | 4 | Sana Biotechnology, Inc. (SANA) | Grant/award (A): 536 @ $0 | EDGAR |
| 2022-10-26 | 4 | Prime Medicine, Inc. (PRME) | Conversion (C): 5,728,297 · Conversion (C): 5,728,297 · Purchase (P): 400,000 @ $17 · Purchase (P): 400,000 @ $17 · Conversion (C): 16,080 · Conversion (C): 16,666,667 (derivative) @ $0 · +4 more | EDGAR |
| 2022-10-06 | 4 | Sana Biotechnology, Inc. (SANA) | Grant/award (A): 321 @ $0 | EDGAR |
| 2022-09-15 | 4 | Codiak BioSciences, Inc. (CDAK) jointly with ARCH Venture Fund VIII, L.P., ARCH Venture Fund VIII Overage, L.P., CRANDELL KEITH, BYBEE CLINTON, ARCH Venture Partners VIII, LLC, ARCH Venture Partners VIII, L.P. | Purchase (P): 5,000,000 @ $1.50 · Purchase (P): 5,000,000 (derivative) | EDGAR |
| 2022-09-07 | 4 | Vir Biotechnology, Inc. (VIR) | Other (J): 196,003 @ $0 · Other (J): 253,997 @ $0 · Other (J): 24,737 @ $0 · Other (J): 1,508 @ $0 · Other (J): 239,559 @ $0 · Other (J): 310,441 @ $0 · +2 more | EDGAR |
| 2022-09-01 | 4 | Vir Biotechnology, Inc. (VIR) | Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · Other (J): 27,489 @ $0 · Other (J): 1,684 @ $0 · Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · +2 more | EDGAR |
| 2022-08-26 | 4 | Vir Biotechnology, Inc. (VIR) | Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · Other (J): 27,489 @ $0 · Other (J): 1,684 @ $0 · Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · +2 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-21 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1219042 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs